207 related articles for article (PubMed ID: 32830463)
21. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
Peeva E; Hodge MR; Kieras E; Vazquez ML; Goteti K; Tarabar SG; Alvey CW; Banfield C
Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897
[TBL] [Abstract][Full Text] [Related]
22. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
[TBL] [Abstract][Full Text] [Related]
23. Abrocitinib in atopic dermatitis: review of the current literature and clinical trials.
Napolitano M; Fornaro L; Potestio L; Fabbrocini G; Patruno C
Drugs Today (Barc); 2022 Aug; 58(8):373-387. PubMed ID: 35983924
[TBL] [Abstract][Full Text] [Related]
24. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
Blauvelt A; Boguniewicz M; Brunner PM; Luna PC; Biswas P; DiBonaventura M; Farooqui SA; Rojo R; Cameron MC
J Dermatolog Treat; 2022 Aug; 33(5):2605-2613. PubMed ID: 35763326
[TBL] [Abstract][Full Text] [Related]
25. Abrocitinib for the treatment of atopic dermatitis.
Crowley EL; Nezamololama N; Papp K; Gooderham MJ
Expert Rev Clin Immunol; 2020 Oct; 16(10):955-962. PubMed ID: 32969750
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of abrocitinib for moderate-to-severe atopic dermatitis.
Labib A; Yosipovitch G
Expert Rev Clin Immunol; 2022 Nov; 18(11):1107-1118. PubMed ID: 36173402
[TBL] [Abstract][Full Text] [Related]
27. TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial.
Forman SB; Pariser DM; Poulin Y; Vincent MS; Gilbert SA; Kieras EM; Qiu R; Yu D; Papacharalambous J; Tehlirian C; Peeva E
J Invest Dermatol; 2020 Dec; 140(12):2359-2370.e5. PubMed ID: 32311398
[TBL] [Abstract][Full Text] [Related]
28. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis.
Wojciechowski J; Malhotra BK; Wang X; Fostvedt L; Valdez H; Nicholas T
Clin Pharmacokinet; 2022 May; 61(5):709-723. PubMed ID: 35061234
[TBL] [Abstract][Full Text] [Related]
29. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis.
De SK
Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial.
Flohr C; Cork MJ; Ardern-Jones MR; Eichenfield LF; Barbarot S; Feeney C; Rojo R; Lazariciu I; Nesnas J
J Dermatolog Treat; 2023 Dec; 34(1):2200866. PubMed ID: 37036183
[TBL] [Abstract][Full Text] [Related]
31. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
Fukuyama T; Tschernig T; Qi Y; Volmer DA; Bäumer W
Eur J Pharmacol; 2015 Oct; 764():278-282. PubMed ID: 26164790
[TBL] [Abstract][Full Text] [Related]
32. Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H
Immunotherapy; 2022 Jan; 14(1):5-14. PubMed ID: 34775830
[TBL] [Abstract][Full Text] [Related]
33. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
[TBL] [Abstract][Full Text] [Related]
34. Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Wang EQ; Le V; Winton JA; Tripathy S; Raje S; Wang L; Dowty ME; Malhotra BK
J Clin Pharmacol; 2022 Apr; 62(4):505-519. PubMed ID: 34637151
[TBL] [Abstract][Full Text] [Related]
35. Abrocitinib for the treatment of atopic dermatitis.
Lé AM; Gooderham M; Torres T
Immunotherapy; 2023 Nov; 15(16):1351-1362. PubMed ID: 37667972
[TBL] [Abstract][Full Text] [Related]
36. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
Bissonnette R; Papp KA; Poulin Y; Gooderham M; Raman M; Mallbris L; Wang C; Purohit V; Mamolo C; Papacharalambous J; Ports WC
Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
[TBL] [Abstract][Full Text] [Related]
37. Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Wang EQ; Le V; O'Gorman M; Tripathy S; Dowty ME; Wang L; Malhotra BK
J Clin Pharmacol; 2021 Oct; 61(10):1311-1323. PubMed ID: 33749838
[TBL] [Abstract][Full Text] [Related]
38. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.
Levy LL; Urban J; King BA
J Am Acad Dermatol; 2015 Sep; 73(3):395-9. PubMed ID: 26194706
[TBL] [Abstract][Full Text] [Related]
39. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
[TBL] [Abstract][Full Text] [Related]
40. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.
Klaeschen AS; Nümm TJ; Herrmann N; Leib N; Maintz L; Sakai T; Wenzel J; Bieber T
J Allergy Clin Immunol; 2021 Jun; 147(6):2202-2212.e8. PubMed ID: 33338537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
